Partial virological response to entecavir does not affect long-term clinical outcome in patients with chronic hepatitis B virus (HBV) infection, according to a study presented at The Liver Meeting® 2015.
Patients with chronic hepatitis B virus (HBV) treated with tenofovir rescue monotherapy achieve antiviral efficacy rates similar to those of tenofovir-based combination rescue therapy, even in patients with multi-drug resistance, investigators reported during The Liver Meeting® 2015.
In patients with minimal hepatic encephalopathy, nutritional therapy is effective and improves HRQOL, a randomized controlled trial presented during The Liver Meeting® 2015 has reported.
In patients with minimal hepatic encephalopathy, prophylactic lactulose treatment improves cognition, quality of life, and intestinal microbiota, results of a multicenter, randomized, controlled trial presented at The Liver Meeting® 2015 have shown.
When all patients with hepatitis C virus (HCV) with genotype 3 (GT3) infection are treated with daclatasvir/sofosbuvir, substantially fewer medical events and lower medical costs are accrued” vs. scenarios in which no one is treated or treatment is limited to F3/F4 patients, results of a study using a Markov model presented at The Liver Meeting® 2015 concluded.
Ledipasvir/sofosbuvir with ribavirin treatment for 12 or 24 weeks in patients with decompensated cirrhosis or recurrent hepatitis C virus (HCV) was effective, with low relapse rates, Edward J. Gane, MBChB, MD, from the University of Auckland, Auckland, New Zealand, presented at The Liver Meeting® 2015.
Mild or moderate renal impairment did not impact direct-acting antivirals (DAA) and ritonavir (RTV) exposures, a study presented at The Liver Meeting® 2015 found.
At The Liver Meeting® 2015, researchers reported that the efficacy of dual oral therapy with asunaprevir + daclatasvir was comparable between elderly and non-elderly patients with chronic hepatitis C, including compensated cirrhosis.
Interferon-free ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin showed a more favorable Work Productivity and Activity Impairment (WPAI) profile in treatment-naïve, non-cirrhotic, HCV GT1-infected patients vs. telaprevir + peginterferon/ribavirin (TPV + pegIFN/RBV), reported Yan Liu, MD, PhD, from AbbVie, North Chicago, IL at The Liver Meeting® 2015.
Patients with recurrent hepatitis C virus (HCV) genotype 1 (GT1) infection treated with the “3D+R” regimen post-transplant have a substantially lower likelihood of experiencing compensated or decompensated cirrhosis and death compared with the standard of care, 48 weeks of pegylated interferon plus ribavirin, or no treatment, a study reported at The Liver Meeting® 2015.
Please login or register first to view this content.
